Clemizole
Clemizole inhibits transient receptor potential cation 5 (TRPC5) channels. Clemizole also suppresses replication of hepatitis C virus (HCV) by inhibiting NS4B activity. This compound displays a wide variety of biological activities, including antiviral, anticonvulsant, antiepileptic, and anti-allergic properties. In vivo, clemizole prevents the development of seizures and decreases convulsive behaviors. This compound also may inhibit histamine H1 receptors, suppressing histamine activity.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18852367
| Cas No. |
442-52-4 |
|---|---|
| Purity |
≥98% |
| Formula |
C19H20ClN3 |
| Formula Wt. |
325.84 |
| IUPAC Name |
1-(4-Chlorobenzyl)-2-(1-pyrrolidinylmethyl)-1H-benzimidazole |
Richter JM, Schaefer M, Hill K. Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5. Mol Pharmacol. 2014 Nov;86(5):514-21. PMID: 25140002.
Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun. 2013;4:2410. PMID: 24002024.
Einav S, Sobol HD, Gehrig E, et al. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 2010 Jul 1;202(1):65-74. PMID: 20486856.
